Edition:
United States

Biotec Pharmacon ASA (BIOTEC.OL)

BIOTEC.OL on Oslo Stock Exchange

5.50NOK
21 Jul 2017
Change (% chg)

kr0.00 (+0.00%)
Prev Close
kr5.50
Open
kr5.50
Day's High
kr5.58
Day's Low
kr5.45
Volume
20,991
Avg. Vol
101,520
52-wk High
kr13.60
52-wk Low
kr5.11

Latest Key Developments (Source: Significant Developments)

Biotec appeals UK drug tariff rejection
Friday, 19 May 2017 09:21am EDT 

May 19 (Reuters) - BIOTEC PHARMACON ASA :BIOTEC APPEALS UK DRUG TARIFF REJECTION.SUBSIDIARY BIOTEC BETAGLUCANS HAS FILED APPEAL FOR REJECTION OF UK DRUG TARIFF REIMBURSEMENT.  Full Article

Oslo Bourse takes Grieg, Spb 1 SR Bank, Gaming Innovation and Link Mobility into osebx share index
Friday, 5 May 2017 02:30am EDT 

May 5 (Reuters) - Oslo Bourse says::Oslo Bourse takes Grieg Seafood<<>>, Sparebank 1 SR Bank<<>>, Gaming Innovation<<>> and Link Mobility Group<<>> into OSEBX share index.OSEBX.Norwegian Finance Holding<<>>, Multiconsult<<>>, American Shipping Company<<>> and Biotec Pharmacon<<>> go out of osebx share index.The changes take effect from June 1 2017.  Full Article

Biotec Pharmacon pantent granted in the US
Thursday, 4 May 2017 08:58am EDT 

May 4 (Reuters) - BIOTEC PHARMACON ASA ::PATENT ON TECHNOLOGY PLATFORM SBG GRANTED BIOTEC PHARMACON IN US.  Full Article

Biotec Pharmacon Q1 EBITDA loss widens to NOK 4.1 mln
Thursday, 27 Apr 2017 01:00am EDT 

April 27 (Reuters) - BIOTEC PHARMACON ASA ::Q1 EBITDA LOSS NOK 4.1 MILLION VERSUS LOSS NOK 3.5 MILLION YEAR AGO.Q1 SALES NOK 18.2 MILLION VERSUS NOK 17.3 MILLION YEAR AGO.  Full Article

Biotec Pharmacon's CEO Svein W. F. Lien resigns due to health issues
Thursday, 16 Mar 2017 12:03pm EDT 

Biotec Pharmacon ASA : Biotec Pharmacon's CEO, Svein W. F. Lien resigns due to health issues . Says board has entered into agreement with Lien and will start recruitment process immediately .Says Lien is committed to continue in his full capacity as CEO until a successor is on board, at which time he will step down.  Full Article

Biotec Pharmacon Q4 EBITDA loss widens to NOK 8.1 mln
Thursday, 2 Feb 2017 01:00am EST 

Biotec Pharmacon ASA : Q4 revenue 18.2 million Norwegian crowns ($2.2 million)versus 13.1 million crowns year ago . Q4 EBITDA loss 8.1 million crowns versus loss nok 7.1 million year ago .Operational targets for 2017 are to finalize UK reimbursement, drive commercial sales for Woulgan, expand business opportunities within consumer and animal health segment.  Full Article

Biotec Pharmacon EBITDA loss widens to NOK 5.9 million
Wednesday, 26 Oct 2016 01:00am EDT 

Biotec Pharmacon ASA : Q3 revenue 21.1 million Norwegian crowns ($2.5 million) versus 16.4 million crowns year ago . Q3 EBITDA loss 5.9 million crowns versus loss 3.5 million crowns year ago .Reiterates its 2016 operational targets for Woulgan, presented at company's capital markets day on Feb. 11 2016.  Full Article

Biotec Pharmacon: Arcticzymes launches polymerase product, gets patent in US
Friday, 30 Sep 2016 02:00am EDT 

Biotec Pharmacon ASA : Says subsidiary ArcticZymes has launched its first DNA polymerase product onto market .ArcticZymes also received patent protection for its heat-labile Salt Active Nucleases (SAN) in USA.  Full Article

Biotec Pharmacon Q2 EBITDA loss widens to NOK 1.6 mln
Wednesday, 17 Aug 2016 01:00am EDT 

Biotec Pharmacon ASA : Q2 revenue 15.3 million Norwegian crowns ($1.86 million) versus 11.5 million crowns year ago . Q2 EBITDA loss 1.6 million crowns versus loss 1.0 million crowns year ago .Reiterates its 2016 operational targets for Woulgan.  Full Article

Biotec Pharmacon files 510K application for US market
Thursday, 30 Jun 2016 08:34am EDT 

Biotec Pharmacon ASA : Says will file 510K application for Woulgan for US market this week . Process normally takes 6-9 months .Expects feedback from authorities late in 2016 or early 2017.  Full Article

BRIEF-Biotec appeals UK drug tariff rejection

* SUBSIDIARY BIOTEC BETAGLUCANS HAS FILED APPEAL FOR REJECTION OF UK DRUG TARIFF REIMBURSEMENT Source text for Eikon: Further company coverage: (Gdynia Newsroom)